Free Trial
NASDAQ:FENC

Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis

Fennec Pharmaceuticals logo
$4.23 -0.03 (-0.70%)
(As of 11/12/2024 ET)

About Fennec Pharmaceuticals Stock (NASDAQ:FENC)

Key Stats

Today's Range
$4.14
$4.30
50-Day Range
$4.19
$5.56
52-Week Range
$3.98
$11.92
Volume
97,618 shs
Average Volume
113,026 shs
Market Capitalization
$116.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67
Consensus Rating
Buy

Company Overview

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
41st Percentile Overall Score

FENC MarketRank™: 

Fennec Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat, and ranked 736th out of 986 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Fennec Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Fennec Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Fennec Pharmaceuticals are expected to decrease by -37.50% in the coming year, from $0.08 to $0.05 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fennec Pharmaceuticals is -42.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fennec Pharmaceuticals is -42.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Fennec Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.76% of the float of Fennec Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Fennec Pharmaceuticals has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fennec Pharmaceuticals has recently decreased by 3.26%, indicating that investor sentiment is improving.
  • Dividend Yield

    Fennec Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Fennec Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.76% of the float of Fennec Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Fennec Pharmaceuticals has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fennec Pharmaceuticals has recently decreased by 3.26%, indicating that investor sentiment is improving.
  • News Sentiment

    Fennec Pharmaceuticals has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Fennec Pharmaceuticals this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added Fennec Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,856.00 in company stock.

  • Percentage Held by Insiders

    10.98% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    55.51% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fennec Pharmaceuticals' insider trading history.
Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Stock News Headlines

“This Changes Everything” - Trump Hands Millions Massive IRS Gift
Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…
Fennec Pharmaceuticals (NASDAQ:FENC) Given "Outperform" Rating at Wedbush
Fennec Pharmaceuticals Reports Q3 2024 Financial Results
See More Headlines

FENC Stock Analysis - Frequently Asked Questions

Fennec Pharmaceuticals' stock was trading at $11.22 on January 1st, 2024. Since then, FENC stock has decreased by 62.3% and is now trading at $4.23.
View the best growth stocks for 2024 here
.

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of $0.06 by $0.26. The business earned $7.26 million during the quarter, compared to analyst estimates of $13.67 million. Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative trailing twelve-month return on equity of 53.38%.

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/13/2024
Today
11/12/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/20/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FENC
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.67
High Stock Price Target
$15.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+222.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-16,050,000.00
Pretax Margin
5.58%

Debt

Sales & Book Value

Annual Sales
$21.25 million
Book Value
($0.43) per share

Miscellaneous

Free Float
24,416,000
Market Cap
$116.30 million
Optionable
Optionable
Beta
0.27
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:FENC) was last updated on 11/12/2024 by MarketBeat.com Staff
From Our Partners